Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
European Journal of Gastroenterology & Hepatology|March 23, 2026
Lower drug clearance of adalimumab is associated with proactive therapeutic drug monitoring and mucosal healing in patients with inflammatory bowel diseaseTina Deyhim, Alessandra Saraga, Ajay Gade, et al.
Pharmacogenetics and Genomics|November 3, 2011
Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritisThierry Dervieux, Judith A M Wessels, Joel M Kremer, et al.
Pharmaceutics|February 26, 2025
Ustekinumab Drug Clearance Is Better Associated with Disease Control than Serum Trough Concentrations in a Prospective Cohort of Inflammatory Bowel DiseaseAndres J Yarur, Thierry Dervieux, Ryan Ungaro, et al.
Crohn'S & Colitis 360|February 13, 2023
Performance Characteristics of a Clinical Decision Support Tool for Disease Complications in Crohn's DiseaseCorey A Siegel, Lori S Siegel, Marla C Dubinsky, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 31, 2019
Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus ErythematosusRosalind Ramsey-Goldman, Roberta Vezza Alexander, Elena M Massarotti, et al.
Lupus Science & Medicine|October 9, 2019
Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLEDaniel J Wallace, Roberta Vezza Alexander, Tyler O'Malley, et al.
Crohn'S & Colitis 360|July 30, 2025
Impact of Precision-Guided Dosing on Clinical Decision-Making and Health Care Utilization in Inflammatory Bowel Disease: A Retrospective Pretest/Posttest Real-World StudyRonen Arai, Adria Condino, Bincy P Abraham, et al.
Frontiers in Immunology|March 13, 2024
Corrigendum: Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-αElizabeth A Spencer, Marla C Dubinsky, Michael A Kamm, et al.
Frontiers in Immunology|March 13, 2024
Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-αElizabeth A Spencer, Marla C Dubinsky, Michael A Kamm, et al.
Frontiers in Immunology|February 23, 2026
Therapeutic drug monitoring of adalimumab in hidradenitis suppurativa: a prospective observational studyStella X Chen, Bruna Galvao de O Wafae, Sydney Look-Why, et al.
Pageof 6